{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:39:31Z","timestamp":1769117971981,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tolvaptan slowed the rates of total kidney volume (TKV) growth and renal function decline over a 3-year period in patients with autosomal dominant polycystic kidney disease (ADPKD) enrolled in the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial (NCT00428948). In this post hoc analysis of Japanese patients from TEMPO 3:4, we evaluated whether the effects of tolvaptan on TKV and on renal function are interrelated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred and forty-seven Japanese patients from TEMPO 3:4 were included in this analysis (placebo, <jats:italic>n<\/jats:italic>\u2009=\u200955; tolvaptan, <jats:italic>n<\/jats:italic>\u2009=\u200992). Tolvaptan-treated patients were stratified into the responder group (<jats:italic>n<\/jats:italic>\u2009=\u200937), defined as tolvaptan-treated patients with a net decrease in TKV from baseline to year 3, and the non-responder group (<jats:italic>n<\/jats:italic>\u2009=\u200955), defined as tolvaptan-treated patients with a net increase in TKV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean changes during follow-up in the placebo, responder, and non-responder groups were 16.99%, \u2212\u20098.33%, and 13.95%, respectively, for TKV and \u2212\u200912.61, \u2212\u20098.47, and \u2212\u20098.58\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, respectively, for estimated glomerular filtration rate (eGFR). Compared with the placebo group, eGFR decline was significantly slowed in both the responder and non-responder groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tolvaptan was effective in slowing eGFR decline, regardless of TKV response, over 3\u00a0years in patients with ADPKD in Japan. Treatment with tolvaptan may have beneficial effects on slowing of renal function decline even in patients who have not experienced a reduction in the rate of TKV growth by treatment with tolvaptan.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-020-02009-0","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T11:03:15Z","timestamp":1611140595000},"page":"467-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8612-8368","authenticated-orcid":false,"given":"Shigeo","family":"Horie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Ibuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"2009_CR1","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122\u201330.","journal-title":"N Engl J Med"},{"key":"2009_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"FT Chebib","year":"2016","unstructured":"Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67:792\u2013810.","journal-title":"Am J Kidney Dis"},{"key":"2009_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2215\/CJN.00330705","volume":"1","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1:148\u201357.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2009_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2009_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323\u20136.","journal-title":"Nat Med"},{"key":"2009_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363\u20134.","journal-title":"Nat Med"},{"key":"2009_CR7","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1681\/ASN.2004121090","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang X, Gattone V 2nd, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"2009_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2009_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1124\/jpet.114.213256","volume":"349","author":"M Aihara","year":"2014","unstructured":"Aihara M, Fujiki H, Mizuguchi H, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014;349:258\u201367.","journal-title":"J Pharmacol Exp Ther"},{"key":"2009_CR10","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"2009_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","volume":"19","author":"S Muto","year":"2015","unstructured":"Muto S, Kawano H, Higashihara E, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015;19:867\u201377.","journal-title":"Clin Exp Nephrol"},{"key":"2009_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"2009_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3:4 study. Am J Kidney Dis. 2011;57:692\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2009_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"2009_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","volume":"56","author":"M Horio","year":"2010","unstructured":"Horio M, Imai E, Yasuda Y, et al. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32\u20138.","journal-title":"Am J Kidney Dis"},{"key":"2009_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2009_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/kisup.2012.77","volume":"3","author":"The International Society of Nephrology","year":"2013","unstructured":"The International Society of Nephrology. Summary of recommendation statements. Kidney Int Suppl. 2013;3:5\u201314.","journal-title":"Kidney Int Suppl"},{"key":"2009_CR18","doi-asserted-by":"publisher","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif GA, Yamaguchi T, Nivens E, et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 2011;301:F1005\u201313.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2009_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10157-013-0834-4","volume":"18","author":"E Higashihara","year":"2014","unstructured":"Higashihara E, Nutahara K, Okegawa T, et al. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2014;18:157\u201365.","journal-title":"Clin Exp Nephrol"},{"key":"2009_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/jcph.1370","volume":"59","author":"S Lanke","year":"2019","unstructured":"Lanke S, Shoaf SE. Population pharmacokinetic analyses and model validation of tolvaptan in subjects with autosomal dominant polycystic kidney disease. J Clin Pharmacol. 2019;59:763\u201370.","journal-title":"J Clin Pharmacol"},{"key":"2009_CR21","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Gansevoort RT, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol. 2017;28:1592\u2013602.","journal-title":"J Am Soc Nephrol"},{"key":"2009_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","volume":"61","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Meijer E, Li J, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2009_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","volume":"96","author":"RT Gansevoort","year":"2019","unstructured":"Gansevoort RT, van Gastel MDA, Chapman AB, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019;96:159\u201369.","journal-title":"Kidney Int"},{"key":"2009_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13293-016-0063-0","volume":"7","author":"M Perinpam","year":"2016","unstructured":"Perinpam M, Ware EB, Smith JA, et al. Key influence of sex on urine volume and osmolality. Biol Sex Differ. 2016;7:12.","journal-title":"Biol Sex Differ"},{"key":"2009_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","volume":"1","author":"MV Irazabal","year":"2016","unstructured":"Irazabal MV, Blais JD, Perrone RD, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial. Kidney Int Rep. 2016;1:213\u201320.","journal-title":"Kidney Int Rep"},{"key":"2009_CR26","first-page":"1857","volume":"32","author":"MV Irazabal","year":"2017","unstructured":"Irazabal MV, Abebe KZ, Bae KT, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017;32:1857\u201365.","journal-title":"Nephrol Dial Transplant"},{"key":"2009_CR27","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/ndt\/gfg277","volume":"18","author":"P Bardoux","year":"2003","unstructured":"Bardoux P, Bruneval P, Heudes D, et al. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant. 2003;18:1755\u201363.","journal-title":"Nephrol Dial Transplant"},{"key":"2009_CR28","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1073\/pnas.96.18.10397","volume":"96","author":"P Bardoux","year":"1999","unstructured":"Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci U S A. 1999;96:10397\u2013402.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2009_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/CS20080140","volume":"116","author":"SS Bhandari","year":"2009","unstructured":"Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci. 2009;116:257\u201363.","journal-title":"Clin Sci"},{"key":"2009_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/TP.0b013e3181b11ae4","volume":"88","author":"E Meijer","year":"2009","unstructured":"Meijer E, Bakker SJ, de Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009;88:561\u20137.","journal-title":"Transplantation"},{"key":"2009_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.arcmed.2018.04.002","volume":"49","author":"ML Villela-Torres","year":"2018","unstructured":"Villela-Torres ML, Higareda-Mendoza AE, G\u00f3mez-Garc\u00eda A, et al. Copeptin plasma levels are associated with decline of renal function in patients with type 2 diabetes mellitus. Arch Med Res. 2018;49:36\u201343.","journal-title":"Arch Med Res"},{"key":"2009_CR32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ki.2009.267","volume":"76","author":"N Perico","year":"2009","unstructured":"Perico N, Zoja C, Corna D, et al. V1\/V2 vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int. 2009;76:960\u20137.","journal-title":"Kidney Int"},{"key":"2009_CR33","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-02009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-020-02009-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-02009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T08:11:26Z","timestamp":1618128686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-020-02009-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2009"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-02009-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"2 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.H. has received advisory board fees, lecture fees, and grant support as an endowed department from Otsuka Pharmaceutical Co., Ltd. and advisory board fees from Sanofi. S.M. has received lecture fees from Otsuka Pharmaceutical Co., Ltd. and belongs to an endowed department sponsored by Otsuka Pharmaceutical Co., Ltd. H.K. belongs to an endowed department sponsored by Otsuka Pharmaceutical Co., Ltd. T.O., Y.S., and T.I. are full-time employees of Otsuka Pharmaceutical Co., Ltd. K.N. is a former employee of Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"TEMPO 3:4 was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and in compliance with good clinical practice guidelines. The protocol was approved by the institutional review board (IRB) at each trial site. The first patient was enrolled in Niigata University Medical and Dental Hospital (IRB approval number: CH19-002a).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Written informed consent was obtained from all participating patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}